NEW YORK – The lack of diversity in public genomic databases may be inflating tumor mutational burden (TMB) measurements and leading to inappropriate use of immunotherapy, especially among Black cancer patients, recent research suggests.
NEW YORK – The lack of diversity in public genomic databases may be inflating tumor mutational burden (TMB) measurements and leading to inappropriate use of immunotherapy, especially among Black cancer patients, recent research suggests.
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.